Clinical Trial Update: A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive Mutations and Brain Metastasis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating furmonertinib in combination with anlotinib as first-line therapy for advanced non-small cell lung cancer with EGFR-sensitive …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Furmonertinib (furmonertinib)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: NSCLC | Phase 2 | Status: RECRUITING